Literature DB >> 27486112

No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.

Mark S Sulkowski1, Wan-Long Chuang2, Jia-Horng Kao3, Jenny C Yang4, Bing Gao4, Diana M Brainard4, Kwang-Hyub Han5, Edward Gane6.   

Abstract

Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a clinical trial of ledipasvir-sofosbuvir in Taiwan and Korea. Of the 173 patients enrolled, 103 (60%) had been previously infected with HBV. None showed evidence of HBV reactivation.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  ALT flare; HBV reactivation; HCV/HBV coinfection

Mesh：

Substances：

Year:  2016        PMID： 27486112      PMCID： PMC6276897          DOI： 10.1093/cid/ciw507

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Editorial Commentary: Another Call to Cure Hepatitis B.

Authors:  Ashwin Balagopal; Chloe L Thio
Journal:  Clin Infect Dis       Date:  2015-06-16       Impact factor: 9.079

2.  Treating hepatitis B virus/hepatitis C virus coinfected patients with direct-acting hepatitis C virus antivirals only is not safe.

Authors:  Resat Ozaras; Mustafa Sunbul; Mehmet Parlak; Hurrem Bodur; Hakan Leblebicioglu
Journal:  Hepatology       Date:  2016-05-24       Impact factor: 17.425

3.  Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.

Authors:  Anne De Monte; Johan Courjon; Rodolphe Anty; Eric Cua; Alissa Naqvi; Véronique Mondain; Jacqueline Cottalorda; Laurence Ollier; Valérie Giordanengo
Journal:  J Clin Virol       Date:  2016-03-03       Impact factor: 3.168

4.  Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities.

Authors:  Christopher S Murrill; Howard Weeks; Brian C Castrucci; Hillard S Weinstock; Beth P Bell; Catherine Spruill; Marta Gwinn
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

5.  Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir.

Authors:  Jeffrey M Collins; Kara Loren Raphael; Charles Terry; Emily J Cartwright; Anjana Pillai; Frank A Anania; Monica M Farley
Journal:  Clin Infect Dis       Date:  2015-06-16       Impact factor: 9.079

6.  Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV.

Authors:  Edward J Gane; Robert H Hyland; Di An; Evguenia S Svarovskaia; Diana Brainard; John G McHutchison
Journal:  Antivir Ther       Date:  2016-07-01

7.  Reactivation of hepatitis B.

Authors:  Jay H Hoofnagle
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

8.  Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.

Authors:  Wan-Long Chuang; Rong-Nan Chien; Cheng-Yuan Peng; Ting-Tsung Chang; Gin-Ho Lo; I-Shyan Sheen; Horng-Yuan Wang; Jyh-Jou Chen; Jenny C Yang; Steven J Knox; Bing Gao; Kimberly L Garrison; Hongmei Mo; Phillip S Pang; Yu-Chun Hsu; Tsung-Hui Hu; Chi-Jen Chu; Jia-Horng Kao
Journal:  J Gastroenterol Hepatol       Date:  2016-07       Impact factor: 4.029

9.  Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection.

Authors:  Zhihua Liu; Jinlin Hou
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

10.  Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report.

Authors:  Alexander R Ende; Nina H Kim; Matthew M Yeh; Jason Harper; Charles S Landis
Journal:  J Med Case Rep       Date:  2015-07-28
View more
  12 in total

1.  Reply to Ozaras et al.

Authors:  Mark S Sulkowski; Diana M Brainard; Jenny C Yang; Edward J Gane
Journal:  Clin Infect Dis       Date:  2017-05-15       Impact factor: 9.079

Review 2.  Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.

Authors:  Xian-Wan Jiang; Jian-Zhong Ye; Ya-Ting Li; Lan-Juan Li
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 3.  Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era.

Authors:  Jennifer J Chang; Neaka Mohtashemi; Debika Bhattacharya
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

Review 4.  Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies.

Authors:  Danielle J Smalls; Reagan E Kiger; LeAnn B Norris; Charles L Bennett; Bryan L Love
Journal:  Pharmacotherapy       Date:  2019-11-03       Impact factor: 4.705

5.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2022-04-01

Review 6.  Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV).

Authors:  Jason T Blackard; Kenneth E Sherman
Journal:  Rev Med Virol       Date:  2018-05-15       Impact factor: 6.989

7.  Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection.

Authors:  Chen-Hua Liu; Chun-Jen Liu; Tung-Hung Su; Yu-Jen Fang; Hung-Chih Yang; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Open Forum Infect Dis       Date:  2017-02-11       Impact factor: 3.835

Review 8.  Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.

Authors:  Gabriele Fabbri; Ilaria Mastrorosa; Alessandra Vergori; Valentina Mazzotta; Carmela Pinnetti; Susanna Grisetti; Mauro Zaccarelli; Adriana Ammassari; Andrea Antinori
Journal:  BMC Infect Dis       Date:  2017-03-01       Impact factor: 3.090

9.  Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.

Authors:  Ghias Un Nabi Tayyab; Shafqat Rasool; Bilal Nasir; Ghazala Rubi; Abdul-Badi Abou-Samra; Adeel A Butt
Journal:  BMC Gastroenterol       Date:  2020-04-06       Impact factor: 3.067

Review 10.  Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV).

Authors:  Mariantonietta Pisaturo; Margherita Macera; Loredana Alessio; Federica Calò; Nicola Coppola
Journal:  Viruses       Date:  2019-09-13       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.